Broad Therapeutic Application
Promising New Therapies
A tidal wave of promising new therapies with the ability to cure diseases are on the horizon.
Non-viral Gene Therapy
Non-viral gene therapy has been extensively studied as a tool for intracellular gene transfer and gene therapy. Recent advancements have brought this delivery option to a place of broad potential therapeutic application due to favorable properties.
Already approved CAR T immuno-oncology therapies: Kymriah® & Yescarta®
Gene modified cell therapies in development:
- Phase I 158
- Phase II 188
- Phase III 16
- Total 362
Source: Alliance for Regenerative Medicine, State of the Industry Briefing, Jan. 2019
Yet the industry remains challenged by:
- the high cost to make virus based genetic modification
- the inability to supply the virus based modification reagents
- the cargo size constraints of virus-based systems
B-MoGen is working to bring a next generation non-viral genetic modification platform to therapeutic drug developers to address these challenges.
Kymriah® is a registered trademark of Novartis Pharmaceuticals Corporation.
Yescarta® is a registered trademark of KITE Pharma, Inc.